Diagnostic agent developer Lantheus Medical Imaging has inked a five-year molybdenum-99 (Mo-99) supply contract with the Institute for Radioelements (IRE).
Lantheus will use the IRE-supplied Mo-99 in its TechneLite technetium-99 (Tc-99m) generators. The agreement, which runs through December 31, 2017, is designed to make Lantheus less vulnerable to supply shortages, according to the vendor.
The agreement also provides for the transition to Mo-99 sourced from low-enriched uranium (LEU) targets once IRE completes its ongoing conversion program to modify its facilities and processes in accordance with Belgian nuclear security commitments, Lantheus said.
